Zhengwei Song

Jul 16, 2024 | molecular-cancer.biomedcentral.com | Zhaoyang Zhu |Yigang Jin |Jing Zhou |fei chen |Minjie Chen |Zhaofeng Gao | +5 more

Currently, PD1/PD-L1 inhibitors have become an important class of immunotherapy in the treatment of ccRCC. Their clinical efficacy has been validated in multiple clinical trials. In this section, we will summarize the main clinical trial data of PD1/PD-L1 inhibitors in the treatment of ccRCC, including the trial results of drugs such as Nivolumab and Pembrolizumab. We will explore the efficacy of PD1/PD-L1 inhibitors, common resistance mechanisms, and strategies to address resistance.

May 26, 2023 | aging-us.com | Chenxi Cao |Hai Zhong |Zhenwei Chen |Zhengwei Song

Research Paper Volume 15, Issue 10 pp 4524—4532 1 Department of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing 314001, Zhejiang, China * Co first-author https://doi.org/10.18632/aging.204757 How to Cite Copyright: © 2023 Cao et al.

May 26, 2023 | aging-us.com | Chenxi Cao |Hai Zhong |Zhenwei Chen |Zhengwei Song

Research Paper Volume 15, Issue 10 pp 4524—4532 1 Department of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing 314001, Zhejiang, China * Co first-author https://doi.org/10.18632/aging.204757 How to Cite Copyright: © 2023 Cao et al.